Investment Rating - The report maintains an "Outperform" rating for the industry [5][25]. Core Insights - The outlook for 2026 marks the beginning of the Fifteenth Five-Year Plan, with a focus on high-quality development driven by regulatory requirements. The current new housing market, valued at 8 trillion RMB, shows some capacity for sales, emphasizing the importance of fiscal efforts and the timing of blue-chip competition [5][30]. - In December 2025, the top 100 real estate companies achieved a monthly sales amount of 3.13 trillion RMB, reflecting a year-on-year decline of 19.0%, but a narrowing of the decline by 0.9 percentage points compared to November 2025. Equity sales reached 2.46 trillion RMB, down 20.1% year-on-year, with an equity ratio of 79% [5][30]. - The report highlights that most top 100 companies experienced negative year-on-year sales growth in December 2025, with the highest sales recorded by China Overseas Land & Investment at 38 billion RMB [19][30]. Summary by Sections Sales Performance - In December 2025, the top 100 real estate companies' sales amounted to 324.65 billion RMB, up 39.3% month-on-month but down 26.1% year-on-year. Equity sales were 261.53 billion RMB, up 42.0% month-on-month and down 28.7% year-on-year [7][19]. - The top 50 companies recorded sales of 273.41 billion RMB, down 18.6% year-on-year, with equity sales of 211.44 billion RMB, down 18.8% year-on-year [7][19]. Company Recommendations - The report recommends several companies for investment: 1) Development: A-Shares - China Vanke, Poly Developments, China Merchants Shekou, Beijing Urban Construction, Hangzhou Binjiang, Gemdale; H-Shares - China Overseas Land, C&D International [25][30]. 2) Commercial Residential: China Resources Land, Longfor Group [25][30]. 3) Property: Onewo, China Resources Mixc, China Overseas Property, Poly Property, China Merchants Property, ChongQing New DaZheng [25][30]. 4) Cultural Tourism: Shenzhen Overseas Chinese Town [25][30]. Monthly Sales Trends - In December 2025, the top 11-20 companies had a sales threshold decrease of 4.3%, while the top 51-100 companies saw a more significant decline of 28.5% [16][30]. - Among the top 50 companies, 9 achieved positive year-on-year growth, with China State Construction Development leading at 213.2% [19][30].

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical industry [1]. Core Insights - On December 19, the U.S. government announced agreements with 14 pharmaceutical companies, including major players like Amgen, Gilead, and Novartis, to implement Most-Favored-Nation (MFN) pricing, which includes price reductions for certain medications and increased domestic investment [6][17]. - The agreements entail a commitment of at least $150 billion in domestic production investments from the participating companies [18]. - Price reductions are primarily focused on Medicaid and direct sales channels, which are expected to have a limited impact on overall revenue for the companies involved [19]. Summary by Sections MFN Negotiations - The MFN negotiations are nearing completion, with 14 pharmaceutical companies reaching agreements with the government, covering aspects such as Medicaid price reductions and international pricing alignment for new drugs [6][17]. - The agreements include provisions for lowering costs of chronic disease medications and implementing MFN pricing for all listed innovative drugs [18]. Impact on Tariffs and Market Reaction - The MFN agreements provide a three-year exemption from tariffs, alleviating previous uncertainties regarding trade policies affecting the pharmaceutical industry [14][19]. - Following the announcement, the XBI index rose by 2.85%, indicating a neutral to optimistic market reaction to the agreements [11]. Specific Measures and Commitments - Companies are required to lower costs for chronic disease medications, including those for type 2 diabetes and rheumatoid arthritis, through direct sales channels [6][18]. - The agreements also stipulate that companies will donate active pharmaceutical ingredients to a strategic reserve to reduce reliance on foreign sources [7][18].

Investment Rating - The report gives an "Outperform" rating for the company, with a target market value of 10.23 billion RMB and a target price of 6.61 USD based on a 15x PE for 2026 [4][17]. Core Insights - The second-hand trading platform is in a rapid growth phase, with significant competitive advantages in sourcing quality supply and pricing power. The company is exploring category expansion and steadily advancing its international business [1][4]. - The company is a leader in the domestic circular economy for second-hand goods, transitioning from a single recycling platform to a full industry chain service provider [21][22]. - The company benefits from the rational consumption trend and the increasing availability of quality social inventory, particularly in the 3C category, driven by policies encouraging trade-ins and product replacement cycles [4][25]. Financial Summary - Total revenue is projected to grow from 12,966 million RMB in 2023 to 32,253 million RMB in 2027, with year-on-year growth rates of 31.4%, 25.9%, 28.1%, 25.0%, and 23.3% respectively [3][16]. - Adjusted net profit is expected to increase from 225 million RMB in 2023 to 1,028 million RMB in 2027, with significant year-on-year growth rates of 342.9%, 39.5%, 27.7%, 70.1%, and 50.8% [3][15]. - The adjusted operating profit margin is projected to improve from 1.9% in 2023 to 3.7% in 2027 [3][15]. Business Model and Strategy - The company has established a comprehensive service system covering the entire supply chain from recycling to sales, utilizing a digital and supply chain-centric approach to enhance efficiency and transparency [31][32]. - The company operates through multiple platforms, including C2B, B2B, and B2C models, to facilitate standardized recycling and efficient circulation of idle consumer electronics [32][37]. - Strategic partnerships, particularly with JD.com, provide significant advantages in sourcing quality supply and enhancing market reach [43][4]. Market Dynamics - The second-hand electronic product trading market in China is expected to reach 858 billion RMB by 2025, with a growth rate of 21% [9]. - The company is well-positioned to benefit from the increasing trade-in rates and the elongation of replacement cycles for smartphones, which are critical for driving demand in the second-hand market [4][25].

Rate Decision Insights - The Federal Reserve's December FOMC minutes revealed a significant internal split, with a 9-3 vote to cut the federal funds rate by 25 basis points to a target range of 3.5%-3.75%[1] - The dissenting votes included two members advocating for no change and one member calling for a more aggressive 50 basis point cut[1] - The majority favored the rate cut due to increased downside risks to employment and stable inflation risks, suggesting further cuts may be appropriate if inflation trends downward[2] Economic Conditions - Overall PCE inflation and core PCE inflation both stood at 2.8%, with goods inflation influenced by tariffs and service inflation showing signs of moderation[2] - The unemployment rate increased slightly to 4.4%, indicating a softening labor market, while hiring activity remained weak[2] Market Expectations - Prior to the meeting, options markets anticipated a 25 basis point cut and projected two additional cuts in 2026[2] - Following the release of the minutes, equity markets experienced a slight decline, with traders increasing bets on a potential rate cut in April[4] Future Policy Guidance - All participants agreed that future policy decisions will depend on incoming data and evolving economic conditions, with no predetermined path[9] - The uncertainty surrounding the selection of the next Fed Chair adds additional variables to the Fed's independence and future policy direction[10]

Investment Rating - The report assigns an "Outperform" rating to multiple companies including Nike, Midea Group, JD Group, Haier Smart Home, Gree Electric, and others, while Lulu Lemon is rated as "Neutral" [1]. Core Insights - Duty-free sales have shown exceptional performance, driving growth in the discretionary sector, while Hong Kong consumer stocks have experienced significant declines [4][11]. - The luxury goods sector has outperformed, with a weekly increase of 1.5%, while the retail sector also saw a rise of 1.1% [5][13]. - The report highlights that the overall sentiment in travel-related sectors remains high, contributing positively to the discretionary consumption outlook [3]. Weekly Performance Review - The weekly performance of various sectors is as follows: luxury goods > retail > overseas sportswear > overseas cosmetics > US hotels > domestic sportswear > credit cards > snacks > pets > domestic cosmetics > gold and jewelry > gaming, with respective weekly changes of 1.5%, 1.1%, 0.8%, -0.3%, -0.4%, -2.4%, -2.4%, -2.8%, -2.9%, -4.5%, -4.6%, and -5.6% [11][12]. - The retail sector's growth was significantly driven by China Duty Free, which saw a 7.6% increase due to strong sales during the New Year holiday [6][13]. Monthly and Year-to-Date Performance - Monthly performance shows retail leading with a 4.9% increase, followed by overseas sportswear and US hotels, while domestic cosmetics and gaming sectors faced declines [11]. - Year-to-date performance indicates that overseas cosmetics and US hotels have performed well, while domestic cosmetics and snacks have shown negative growth [12]. Valuation Analysis - The report notes that the valuation of various sectors remains below their average over the past five years, with expected PE ratios for 2025 indicating significant potential for growth [9][14]. - Specific sectors such as overseas sportswear are projected to have a PE of 31.2 times, which is 59% of the past five-year average, while domestic sportswear is at 13.3 times, 70% of the average [14][15].

Investment Rating - The report does not explicitly state an investment rating for the Hong Kong Casinos & Gaming industry Core Insights - Macau's gaming gross revenue (GGR) for December 2025 reached MOP 20.888 billion, reflecting a year-on-year increase of 14.8% and a month-on-month decrease of 0.9%, achieving 91.5% of the 2019 level [1][14] - The average daily GGR in December was MOP 674 million, down 4.1% from November's MOP 703 million, indicating resilience in the industry during the traditional peak season for family travel [1][14] - For the third quarter of 2025, Macau's GGR was MOP 66.062 billion, up 15% year-on-year and 5.6% quarter-on-quarter, also reaching 91.6% of the 2019 level [1][14] - The total GGR for Macau in 2025 was MOP 247.403 billion, a 9.1% increase year-on-year, recovering to 84.6% of the 2019 level, with expectations for a 9% growth in 2026, reaching 92.2% of the 2019 level [1][14] Summary by Sections Monthly GGR and Year-on-Year Growth - December GGR decreased by 0.9% month-on-month but increased by 14.8% year-on-year, recovering to 91.5% of the 2019 level [1][14] - The average daily GGR in December was MOP 674 million, down from MOP 703 million in November [1][14] Visitor Statistics - In November 2025, the number of inbound visitors to Macau was 3.35 million, up 18.1% year-on-year and 115% of the 2019 level [3][15] - The number of visitors from mainland China was 2.4 million, representing a 21.9% year-on-year increase [3][15] Hotel Occupancy Rates - The hotel occupancy rate in Macau for November 2025 was 90.2%, an increase of 0.7 percentage points year-on-year and 1.1 percentage points month-on-month [4][16] - The average stay time for hotel guests was stable at 1.7 nights [4][16]

Investment Focus - The report emphasizes prioritizing midstream dairy companies for consumer staples exposure in China, suggesting that this sector is expected to recover first in terms of performance and valuation [1][6]. Industry Overview - In December 2025, among the eight tracked essential consumer sectors, four showed positive growth while four experienced declines. The growing sectors included condiments, frozen foods, soft drinks, and dining, while the declining sectors were premium and mass-market baijiu, dairy products, and beer [3][9]. - The report indicates that the overall demand in most sectors remains subdued, with traditional categories like baijiu, beer, and dairy under pressure due to weakened consumer sentiment and competition from substitutes [3][9]. Price Trends - Baijiu wholesale prices mostly stabilized in December, with notable price changes for various brands. For instance, the price for Moutai (飞天) was reported at 1600 RMB for a full box, down 50 RMB from the previous month [4][22]. - Discounts on liquid milk and convenience foods increased significantly, reflecting a lack of demand, while discounts on condiments and soft drinks decreased [4][36]. Cost Analysis - The cost index for six categories of consumer goods showed mixed results in December, with soft drinks and instant noodles experiencing slight increases, while dairy products and beer saw modest declines [4][5]. - The prices of raw materials such as aluminum cans and paper increased year-on-year, impacting overall production costs [4]. Market Capitalization and Valuation - As of the end of December, net inflows into Hong Kong Stock Connect amounted to 20.825 billion RMB, with the consumer staples sector's market capitalization share rising to 5.61% [5]. - The report notes that the historical PE ratio for A-share food and beverage companies was at 16% (20.3x), indicating a decrease of 5 percentage points from the previous month [5]. Recommendations - The report suggests a two-pronged investment strategy for January: focusing on high-risk preference stocks like Luzhou Laojiao and Wuliangye, and on stocks with improving fundamentals and dividend yields such as Yili and Mengniu [6].

·········································································································[Table_Title] 研究报告 Research Report 5 Jan 2026 ```··························································································································································································································································· 东南亚可选消费必需消费 Southeast Asia Discretionary Staples 东南亚指数双周报第 15 期：集体拉升，越南领涨 ASEAN Index Tracking： Broad Rall ...

Investment Rating - The report does not explicitly state an investment rating for the automotive industry but indicates a challenging outlook for the market moving into 2026 due to increasing volatility and structural changes [7]. Core Insights - Major automakers reported December and full-year sales results, with a notable decline in the typical year-end "pull-forward" effect, leading to double-digit month-on-month declines for most OEMs [7][8]. - The fading demand driven by subsidies is expected to put sustained pressure on the automotive market in China, with a forecast of increased volatility and market restructuring [7][8]. - The divergence in target fulfillment among automakers reflects the alignment of corporate strategies with actual market demand, with some companies exceeding targets through effective segmentation and cost efficiency [16]. Summary by Relevant Sections December Sales Performance - BYD sold 420,000 units in December, an 18% year-on-year increase but a 13% month-on-month decline, achieving a full-year target of 4.602 million units [8][9]. - Geely's December sales reached 240,000 units, a 13% year-on-year increase but a 24% month-on-month decline, with a full-year target of 3.025 million units achieved [9]. - Leapmotor delivered 60,000 units in December, a 42% year-on-year increase, surpassing its annual target of 500,000 units ahead of schedule [10]. Strategic Positioning and Market Demand - Companies that effectively matched their strategic positioning with market demand were able to meet or exceed their sales targets, while others that relied heavily on specific products or technologies underperformed [16]. - NIO achieved a record 48,000 units in December, with a full-year delivery total of 326,000 units, reflecting a 74% target achievement rate [15]. - Xiaomi Auto exceeded 50,000 units in December for the first time, achieving over 400,000 units for the full year, aligning with its revised guidance [12]. Future Outlook - The report anticipates intensified competition in the electric vehicle segment, particularly for companies like Li Auto, which aims to maintain its leading position while facing uncertainties in its battery electric vehicle strategy [13]. - The overall market dynamics suggest that companies will need to adapt to changing consumer preferences and competitive pressures as they move into 2026 [16].

Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]